| 摘要 |
<p>This invention relates to a method for differentiating patients with cancer of the prostate (PCa) from patients with benign prostatic hyperplasia (BPH) or healthy male subjects without PCa, wherein the individual's body fluid concentration of prostate specific antigen (PSA) has been determined as free PSA, as complexed with α1-antichymotrypsin (PSA-ACT), as complexed with α1-protease inhibitor (PSA-API) and as total PSA. The method is characterized in that the combination of a) PSA-API or a quantity including PSA-API, and b) free PSA, PSA-ACT or total PSA, or any combination of free PSA, PSA-ACT and total PSA, is used as marker distinguishing PCa patients from BPH and other non-PCa individuals, and that said combination of a) and b) as defined above, is a stepwise ROC analysis, a logistic regression analysis combination or a similar statistical method. Furthermore, the invention concerns methods for the purification and stabilizing of a PSA-API complex formed in vitro and useful as calibrator in an immunoassay.</p> |
